Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
from the European Union's drug advisory board, potentially opening the door to broader use of a formulation designed to deliver greater weight loss than the standard dose. The European Medicines Agency's drug review committee supported the higher-dose shot after evaluating results from large clinical trials in people with obesity, both with and without diabetes, according to the company. Novo said the committee's backing could allow the product to become available early in the new year, subject to final approval from the European Commission. Warning! GuruFocus has detected 1 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Novo indicated that weight-loss results from the higher-dose Wegovy could be competitive with Eli Lilly & Co.'s (LLY) Zepbound, underscoring the increasingly competitive landscape in obesity treatments. Management framed the development as part of a broader strategy to expand its semaglutide portfolio, which includes
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]Yahoo! Finance
- Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer [Yahoo! Finance]Yahoo! Finance
- Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancerPR Newswire
- Novo Nordisk Stumbles as Obesity Drug Race Heats Up [Yahoo! Finance]Yahoo! Finance
- Think Eli Lilly Is Expensive? This Metric Says Otherwise. [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/8/25 - Form 3
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- LLY's page on the SEC website